Navigation Links
DelMar Pharmaceuticals Announces Acquisition and $5.4 Million Private Placement to Advance Novel Cancer Therapies
Date:1/25/2013

>. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action.

For further information, please visit www.delmarpharma.com
or contact Jeffrey A. Bacha , President & CEO  (604) 629-5989

Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.


'/>"/>
SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015 BioSpecifics Technologies Corp. ... first in class collagenase-based products marketed as XIAFLEX ® ... and XIAPEX ®  in the EU, announced today that ... webcast at 8:30 a.m. ET on Friday, March 13, ... 2014 financial results and provide a corporate update. ...
(Date:3/6/2015)... , March 6, 2015 ...   2011 von der Assistance Publique - ... initiiert., Sie ist eine französische, gemeinschaftliche, randomisierte ... Patienten rekrutiert wurden. Verglichen werden Patienten mit ... Yttrium-90 Harz-Mikrosphären oder Sorafenib behandelt wurden. Die ...
(Date:3/5/2015)... Paul, Minn. (PRWEB) March 05, 2015 ... in Pasadena this summer at the Annual Meeting of ... are starting to be released online now at ... been announced for the meeting, to be held August ... newly announced Special Sessions, Field Trips, Workshops, and committee ...
(Date:3/5/2015)... 2015  UBM Medica US announces that ... community to help oncologists and other clinicians gain ... regarding the use of targeted therapies and immunotherapies, ... March is National Kidney Cancer Awareness Month ... treatment options for renal cell carcinoma (RCC) patients. ...
Breaking Biology Technology:BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6American Phytopathological Society Announces Annual Meeting Daily Schedule 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 2OncoTherapy Network Highlights Kidney Cancer Awareness Month 3
... ... ... , ... OXFORD, England and LANGHORNE, Pennsylvania, ...
... ... ... , ... ...
... , ... ... ... ...
Cached Biology Technology:EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 2EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 3EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region 4Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 2Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 3Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 4Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 5Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 6Ten Million Flex-Fuel Vehicles in Brazil a Milestone that Deserves Global Dissemination by Automakers 7MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 2MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 3MedShape Solutions, Inc. Announces Commercialization of SBIR Funded Technology: Receives Purchasing Preference in Federally Funded Hospitals and Health Care Facilities 4
(Date:2/24/2015)... 24, 2015 This report analyzes the worldwide markets for ... Face Biometrics, and Voice Biometrics. The report provides separate comprehensive analytics ... , Europe , Asia-Pacific ... , and Latin America . Annual estimates ... a seven-year historic analysis is provided for these markets. Market data ...
(Date:2/23/2015)... Conn. , Feb. 23, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62114357 for DISTRIBUTED ... this patent, NXT-ID introduces a new groundbreaking payment method. ... the payment account may only be accessed if both ...
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3Cepheid to Webcast Upcoming Financial Presentations 2
... device to reduce the risk of infection, clotting and narrowing ... because of kidney failure. The device, designed to be ... a technician easy access to the patient,s bloodstream and could ... of a dialysis procedure. The prototype has not yet ...
... and fidgeting at your desk are contributing more ... Researchers have found that both the duration ... associated with cardiorespiratory fitness. The intensity of the ... cumulative 30-minute increase in moderate physical activity throughout ...
... that could stop the virus in its tracks have come ... Leeds, UK. The study by Dr Stephen Griffin and ... two prototype small molecule drugs, known as p7 inhibitors, can ... findings suggest that p7 inhibitors could be a powerful way ...
Cached Biology News:Student team invents device to cut dialysis risk 2Fidgeting your way to fitness 2Will new drugs block hepatitis C virus in its tracks? 2
... and positioning system is designed for ... be positioned or scanned with high ... superior responsiveness compared to micropositioners with ... or XY stage) are driven by ...
For microscopy...
... and Labeling Kit generates labeled cDNA for ... cDNA is made via a reverse transcription ... primer. Unlike other methods, there are no ... transcription reaction. This unmodified cDNA is then ...
... 'The DNAscope LM is a high quality ... technology for optimal background rejection and spatial resolution. ... is the only low cost microarray scanner that ... excitation sources. Main Features: Includes ...
Biology Products: